Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Seminars in Liver Disease
(ISSN: 0272-8087, 1098-8971)
This journal no longer participates in Medscape Publishers' Circle Program. No new articles will be republished.
This article reviews the promises and challenges in developing and validating biomarkers that could help HCPs distinguish DILI from other causes of liver injury and identify the causative drug.
This article reviews the diagnostic criteria for AIH, the indications for and results of liver transplantation, as well as the management of recurrent AIH disease.
AIH is a treatable disease in the majority of cases, but complex issues such as timely diagnosis, avoidance of treatment side effects, nonresponse and adherence to standard induction therapy remain.
Chronic alcohol consumption has long been associated with progressive liver disease. It may also increase the risk of developing hepatocellular carcinoma, one of the most common malignant tumors.
NAFLD has become commonplace in clinical practice due to the rise of obesity and metabolic syndrome. Without one ideal therapy, what are some of the current and potential future therapies for NAFLD?
Nonalcoholic fatty liver disease is an increasingly recognized cause of liver disease globally. This overview provides an epidemiological background on the prevalence and risk factors for NAFLD.
Vascular tumors of the liver in adult patients include cavernous hemangioma, a common benign tumor; epithelioid hemangioendothelioma, a rare, usually low-grade malignant tumor; and angiosarcoma, a rare and very aggressive tumor.